# A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primar

Source: https://onco.cc/trials/nct06682988/  
OnCo record `nct06682988` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Mirvetuximab soravtansine in ovarian cancer, run by AbbVie, now recruiting.

## Summary

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine is a phase 2 interventional study registered as NCT06682988 by AbbVie, with 110 participants planned, started 2025-05-28 and due to reach its primary completion in 2026-07. Interventions recorded: Mirvetuximab Soravtansine. Conditions listed: Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06682988
- Phase: 2
- Setting: A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment
- Sponsor: AbbVie
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT06682988: https://clinicaltrials.gov/study/NCT06682988

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/)
- companies: [AbbVie (incl. ImmunoGen, Capstan)](https://onco.cc/companies/abbvie/)

---
JSON: https://onco.cc/api/v1/entities/nct06682988.json